`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`C.A. No. _______________
`
`))))))))))))))))))
`
`CEPHALON, INC.,
`
`Plaintiff,
`
`v.
`
`SANDOZ INC.; ACCORD HEALTHCARE,
`INC.; INTAS PHARMACEUTICALS LTD.;
`INNOPHARMA, INC.; AGILA
`SPECIALTIES INC. f/k/a STRIDES, INC.;
`ONCO THERAPIES LIMITED; GLENMARK
`PHARMACEUTICALS LTD.; GLENMARK
`GENERICS LTD.; GLENMARK GENERICS
`S.A.; GLENMARK GENERICS INC., USA;
`EUROHEALTH INTERNATIONAL SARL;
`and WEST-WARD PHARMACEUTICAL
`CORP.,
`
`Defendants.
`
`AMENDED SUPPLEMENTAL INFORMATION FOR PATENT CASES INVOLVING
`AN ABBREVIATED NEW DRUG APPLICATION (ANDA)
`
`Plaintiff(s) hereby provide(s) the information below with respect to the deadlines set forth
`in 21 U.S.C. 355(j):
`
`Date Patentee(s) Received Notice: __________________________
`
`Date of Expiration of the U.S. Patent 8,895,756: January 12, 2026
`
`Thirty Month Stay Deadline:1 ______________________________
`
`February 23, 2015
`Date
`
`/s/Stephen Brauerman
`Attorney(s) for Plaintiff
`
`1 No thirty-month stay is associated with this action. However, there is a thirty-month stay
`In re:
`associated with the co-pending related action filed by Plaintiff Cephalon,
`Inc.
`Bendamustine Consolidated Cases, Civil Action No. 13-2046-GMS (consolidated).